Health Trials

Intraindividual Comparison of EMO IOLs

ConditionAge Related Cataracts
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-100
SponsorMedical University of Vienna

About this trial

The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved investigational plan.

Eligibility criteria

Qualifiers

Bilateral age-related cataract planned for phacoemulsification extraction and posterior IOL implantation

Age 50 to 100

Visual potential in both eyes of 20/25 or better as determined by investigators estimation

Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant

Disqualifiers

Preceding intraocular surgery or ocular trauma

Relevant other ophthalmic diseases that particularly effects the zonular apparatus (such as severe pseudoexfoliation syndrome, preceding cryocoagulation, trauma)

Pupil diameter < 2.0 mm (photopic)

Laser treatment

Trial design

Treatments tested in this trial

  • phacoemulsification and intraocular lens implantation
  • phacoemulsification and intraocular lens implantation
  • phacoemulsification and intraocular lens implantation
  • phacoemulsification and intraocular lens implantation
  • phacoemulsification and intraocular lens implantation
  • phacoemulsification and intraocular lens implantation
  • phacoemulsification and intraocular lens implantation
  • phacoemulsification and intraocular lens implantation
  • phacoemulsification and intraocular lens implantation
  • phacoemulsification and intraocular lens implantation

Treatment groups

461 Participants
are divided into 10 treatment groups

10

Treatment groups

See each treatment group below.

Sponsors and collaborators

Medical University of Vienna

Lead sponsor

Source ClinicalTrials.gov